ReviewFrontiers in cell and developmental biology2022
Inflammasomes in Cancer Progression and Anti-Tumor Immunity.
Review in Frontiers in cell and developmental biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 47 citations in OpenAlex.
- Malaria and cancer: common features and interactions.Trends in parasitology · 2026Review
- Curcumin Attenuates Breast Cancer Cell-induced Inflammasome Activation via the NOD-like receptor protein 3/Caspase-1/Interleukin-1β Axis.Journal of cancer prevention · 2026Article
- Identification of pyroptosis-related molecular subtypes and development of a subtype-derived six-gene prognostic signature for bladder cancer.Translational andrology and urology · 2026Article
- Curcumin Attenuates LPS-Induced Migration/EMT and LPS/ATP-Associated IL-1β Release in Androgen-Independent Prostate Cancer Cells.Current issues in molecular biology · 2026Article
- Inflammasomes in glioblastoma.Journal of neuroinflammation · 2026Review
- Mechanism and role of regulated cell death in tumor immunity and immunotherapy.Cancer communications (London, England) · 2025Review
- Inflammasomes and autophagy in cancer: unlocking targeted therapies.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Damage-associated molecular patterns (DAMPs) in diseases: implications for therapy.Molecular biomedicine · 2025Review
- Review
- p62 mRNA suppresses NLRP1 expression in cutaneous SCC cells through miR-34a-5p.Cell death & disease · 2025Article
- Targeting inflammasomes as an immunotherapeutic strategy for cancer.Journal of translational medicine · 2025Review
- Cholesterol crystals in the pathogenesis of atherosclerosis.Nature reviews. Cardiology · 2025Review
- Inflammasomes in lymphocytes as therapeutic targets.Translational oncology · 2025Article
- Rational therapeutic targeting of myeloid cells in glioblastoma: challenges and perspectives.Frontiers in immunology · 2025Review
- Bioinformatic and experimental data pertaining to the role of the NLRP3 inflammasome in ovarian cancer.Journal of cancer research and clinical oncology · 2024Review
- Celecoxib inhibits NLRP1 inflammasome pathway in MDA-MB-231 Cells.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- Pan-immune-inflammation value and survival in patients with breast cancer from a Peruvian reference hospital.Scientific reports · 2024Article
- RepurposingLife (Basel, Switzerland) · 2024Article
- Unleashing Natural IL18 Activity Using an Anti-IL18BP Blocker Induces Potent Immune Stimulation and Antitumor Effects.Cancer immunology research · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The inflammasomes are critical regulators of innate immunity, inflammation and cell death and have emerged as important regulators of cancer development and control. Inflammasomes are assembled by pattern recognition receptors (PRR) following the sensing of microbial- or danger-associated molecular patterns (MAMPs/DAMPs) and elicit inflammation through the oligomerization and activation of inflammatory caspases. These cysteinyl-aspartate proteases cleave the proinflammatory cytokines IL-1β and IL-18 into their biologically active mature form. The roles of the inflammasomes and associated pro-inflammatory cytokines vary greatly depending on the cancer type. Here we discuss recent studies highlighting contrasting roles of the inflammasome pathway in curbing versus promoting tumorigenesis. On one hand, the inflammasomes participate in stimulating anti-tumor immunity, but they have also been shown to contribute to immunosuppression or to directly promote tumor cell survival, proliferation, and metastasis. A better understanding of inflammasome functions in different cancers is thus critical for the design of novel cancer immunotherapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.